Kai H Liao
Overview
Explore the profile of Kai H Liao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
116
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Williams J, Liao K, Yin D, Meng X
AAPS J
. 2024 Mar;
26(2):31.
PMID: 38453809
The interpretation of immunogenicity results for a mAb product and prediction of its clinical consequences remain difficult, despite enormous advances in methodologies and efforts toward the best practice for consistent...
2.
Guo C, Liao K, Li M, Wang I, Shaik N, Yin D
CPT Pharmacometrics Syst Pharmacol
. 2022 Nov;
12(11):1619-1625.
PMID: 36394153
The optimal dose for targeted oncology therapeutics is often not the maximum tolerated dose. Pharmacokinetic/pharmacodynamic (PK/PD) modeling can be an effective tool to integrate clinical data to help identify the...
3.
Liao K, Williams J, Palani S, Yin D, Meng X
AAPS J
. 2022 Jun;
24(4):73.
PMID: 35688991
Antibody-drug conjugates (ADCs) comprise 3 distinct parts: a specific antibody carrier (mAb), a linker, and a cytotoxic payload. Typical pharmacokinetic (PK) characterization of ADCs remains fragmented using separate noncompartmental analyses...
4.
Li C, Menon R, Walles M, Singh R, Upreti V, Brackman D, et al.
Clin Pharmacol Ther
. 2021 Oct;
112(4):754-769.
PMID: 34657311
Antibody-drug conjugates (ADCs) represent a rapidly evolving area of drug development and hold significant promise. To date, nine ADCs have been approved by the US Food and Drug Administration (FDA)....
5.
Liao K, Udata C, Yin D, Sewell K, Kantaridis C, Alvarez D, et al.
Br J Clin Pharmacol
. 2020 Apr;
86(11):2182-2191.
PMID: 32285955
Aims: Single-dose pharmacokinetic (PK) studies in healthy subjects have been the design of choice for bioequivalence determination for decades. This preference has been recently extended to PK similarity studies of...
6.
Yang R, El-Masri H, Thomas R, Dobrev I, Dennison Jr J, Bae D, et al.
Environ Toxicol Pharmacol
. 2011 Jul;
18(2):65-81.
PMID: 21782736
Because of the pioneering vision of certain leaders in the biomedical field, the last two decades witnessed rapid advances in the area of chemical mixture toxicology. Earlier studies utilized conventional...
7.
Yang Y, Allen B, Tan Y, Liao K, Clewell 3rd H
J Toxicol Environ Health A
. 2010 Apr;
73(12):787-806.
PMID: 20391121
As the initial effort in a multi-step uncertainty analysis of a biologically based cancer model for formaldehyde, a Markov chain Monte Carlo (MCMC) analysis was performed for a compartmental model...
8.
Dobrev I, Nong A, Liao K, Reddy M, Plotzke K, Andersen M
Inhal Toxicol
. 2008 Feb;
20(4):361-73.
PMID: 18302045
The pharmacokinetics of octamethylcyclotetrasiloxane (D4), a highly lipophilic and well-metabolized volatile cyclic siloxane, are more complex than those of other volatile hydrocarbons. The purpose of the present study was to...
9.
Liao K, Tan Y, Conolly R, Borghoff S, Gargas M, Andersen M, et al.
Risk Anal
. 2007 Dec;
27(6):1535-51.
PMID: 18093051
Chloroform is a carcinogen in rodents and its carcinogenicity is secondary to events associated with cytotoxicity and regenerative cell proliferation. In this study, a physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) model that...
10.
Liao K, Tan Y, Clewell 3rd H
Risk Anal
. 2007 Dec;
27(5):1223-36.
PMID: 18076492
A screening approach is developed for volatile organic compounds (VOCs) to estimate exposures that correspond to levels measured in fluids and/or tissues in human biomonitoring studies. The approach makes use...